Jing Wang
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 112
- Cancer Immunotherapy and Biomarkers 33
- Lung Cancer Research Studies 29
- Cancer-related Molecular Pathways 20
-
- Cancer Genomics and Diagnostics 20
- Co-authors
- Craig M. Crews (8 shared papers)John Victor Heymach (43 shared papers)Lixia Diao (40 shared papers)Lauren Byers (34 shared papers)Andrew P. A. Crew (6 shared papers)Hanqing Dong (6 shared papers)John F. Hines (3 shared papers)Yimin Qian (5 shared papers)
- Journals
- Clinical Cancer Research (31 papers)Nature Communications (17 papers)Cancer Research (13 papers)Oncotarget (9 papers)Cancer Discovery (9 papers)
- Partner nations
- United StatesChinaUnited Kingdom
In The Last Decade
Jing Wang
327 papers receiving 27.0k citations
Jing Wang's Hit Papers
Peers
Comparison fields: 5 of 153
- Oncology 11.5k
- Cancer Research 3.7k
- Molecular Biology 13.3k
- Immunology 3.9k
- Pulmonary and Respiratory Medicine 4.9k
Countries citing papers authored by Jing Wang
This map shows the geographic impact of Jing Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jing Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jing Wang more than expected).
Fields of papers citing papers by Jing Wang
This network shows the impact of papers produced by Jing Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jing Wang. The network helps show where Jing Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Jing Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 342 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma Hit paper breakdown → | 2018 | 1296 |
| 2 | Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade Hit paper breakdown → | 2017 | 1077 |
| 3 | Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4 Hit paper breakdown → | 2015 | 947 |
| 4 | Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression Hit paper breakdown → | 2014 | 834 |
| 5 | PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer Hit paper breakdown → | 2016 | 732 |
| 6 | Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead Hit paper breakdown → | 2017 | 728 |
| 7 | Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer Hit paper breakdown → | 2019 | 715 |
| 8 | Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities Hit paper breakdown → | 2021 | 708 |
| 9 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma Hit paper breakdown → | 2018 | 569 |
| 10 | The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study Hit paper breakdown → | 2017 | 557 |
| 11 | STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment Hit paper breakdown → | 2016 | 514 |
| 12 | Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy Hit paper breakdown → | 2018 | 497 |
| 13 | Integrative Molecular Characterization of Malignant Pleural Mesothelioma Hit paper breakdown → | 2018 | 480 |
| 14 | 2013 | 473 | |
| 15 | 2003 | 466 | |
| 16 | 2012 | 451 | |
| 17 | Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome Hit paper breakdown → | 2012 | 433 |
| 18 | Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase Hit paper breakdown → | 2019 | 418 |
| 19 | A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition Hit paper breakdown → | 2015 | 391 |
| 20 | 2018 | 390 |
About Jing Wang
Jing Wang is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Cell Biology, having authored 342 papers that have together received 27.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (49 papers), Cancer Immunotherapy and Biomarkers (33 papers), Lung Cancer Research Studies (29 papers), Cellular transport and secretion (24 papers), Ubiquitin and proteasome pathways (23 papers), Protein Degradation and Inhibitors (21 papers), Cancer-related Molecular Pathways (20 papers) and Cancer Genomics and Diagnostics (20 papers). The work is most often cited by research in Oncology (11.5k citations), Cancer Research (3.7k citations), Molecular Biology (13.3k citations), Immunology (3.9k citations) and Pulmonary and Respiratory Medicine (4.9k citations). Jing Wang has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Craig M. Crews, John Victor Heymach, Lixia Diao, Lauren Byers, Andrew P. A. Crew, Hanqing Dong, John F. Hines, Yimin Qian, Ignacio Ivan Wistuba and Blake E. Smith. Their work appears in journals such as Clinical Cancer Research, Nature Communications, Cancer Research, Oncotarget and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.